Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Alcon Agrees to Acquire STAAR Surgical in Deal Worth $1.5 Billion
—STAAR’s Evo ICL fills a strategic gap in Alcon’s surgical portfolio, broadening its refractive product line while bolstering STAAR’s global commercialization. The Deal: Alcon will acquire STAAR Su...
US FDA Approves Lenz’ Vizz (Aceclidine) Drops for Presbyopia
Lenz Therapeutics announced July 31 that the US FDA had approved Vizz (aceclidine ophthalmic solution) 1.44% for presbyopia. The company said Vizz was the first once-daily, preservative-free eye dr...
Q2-2025 Ophthalmic Revenue Roundup for Roche, Bausch + Lomb, Apellis, Glaukos, and Astellas
Swiss company Roche reported July 24 that Vabysmo sales for Q2-2025 were CHF 1.05 billion ($1.3 billion, converted June 30, 2025), a 19 percent increase over CHF 947 million in Q2-2024. Roche said ...
CMS Proposes Lower Physician Payments in 2026, Higher HOPD and ASC Fees
US ophthalmologists are gaining some clarity on what their reimbursement for treating Medicare patients may look like in 2026. Documents published by the Centers for Medicare and Medicaid Services ...
Boehringer Ingelheim and Re-Vana Sign Potential $1 Billion Collaboration Deal
Boehringer Ingelheim and Re-Vana Therapeutics will collaborate to develop extended-release therapies for eye diseases in a deal worth potentially more than $1 billion for Re-Vana, the companies ann...
Alcon Launches Tryptyr (Acoltremon) Drops for Dry Eye in US
Alcon announced July 29 the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% to treat the signs and symptoms of dry eye. Tryptyr is a first-in-class TRPM8 agonist, dose...
New Minnesota Law Expands ODs’ Authority to Prescribe Drugs, Perform Injections
A new law passed in Minnesota expands optometrists’ authority to prescribe certain medications and allows them to administer some in-office injections. The Minnesota Optometric Association (MOA) ha...
Innovia Medical Acquires Ophthalmic Surgical Instrument Maker Hurricane Medical
Innovia Medical, of St. Paul, Minnesota, reported July 2 that it had acquired Bradenton, Florida-based Hurricane Medical, manufacturer of ophthalmic surgical instruments, as well as Memphis, Tennes...
Glaukos Acquires Mobius Therapeutics and its Mitosol Antifibrotic Agent
Glaukos announced during its earnings call on July 30 that it had acquired Mobius Therapeutics, of St. Louis, Missouri, whose lead compound, Mitosol, is the only FDA approved ophthalmic formulation...
Aflibercept Biosimilar Candidate from Alteogen Gains Positive CHMP Opinion
South Korea’s Alteogen announced July 28 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended approval for Eyluxvi (ALT-L9), its proposed biosi...
UM Whole Eye Transplant Project Overcomes Two Hurdles
Two critical pieces needed to eventually transplant a whole eye have been created and tested successfully at the University of Miami, the school reported July 24. Seventeen UM faculty members are w...
Exonate Plans Phase IIb Trial of Retinal Eye Drop Candidate in NPDR
British company Exonate announced July 29 that it planned a Phase IIb clinical trial for lead compound EXN407, an eye drop candidate targeting retinal vascular diseases, in patients with non-prolif...
Past News Stories
Unity Board Dissolves Company, Ending Research Targeting Senescent Cells
Unity Biotechnology’s board agreed on June 27 to dissolve the South San Francisco, California, company after evaluating strategic alternatives. The Nasdaq delisted Unity’s stock on July 9. Both mov...
Santen Launches Ryjunea Drops in Germany for Pediatric Myopia
Japan’s Santen Pharmaceutical announced July 22 that it had launched Ryjunea low-dose atropine eye drops in Germany for pediatric myopia. Germany is the first market for Ryjunea, which received EU ...
George Tidmarsh, MD, PhD, Named to Lead FDA’s Center for Drug Evaluation and Research
The US FDA reported July 21 that George Tidmarsh, MD, PhD, had been named director of the Center for Drug Evaluation and Research. Tidmarsh, a Stanford University faculty member and physician scien...
First Patient Treated in US Trial of Eyetronic Optic Nerve Therapy for Glaucoma
The Glaucoma Center of San Francisco announced July 21 that it had treated the first patient in the US as part of a clinical trial of Eyetronic, a non-invasive therapy to stimulate the optic nerve....
Octane Examines Changing Refractive Surgery Landscape
The 2025 Octane Ophthalmology Tech Forum examined why lens-based procedures are gaining momentum at the expense of traditional refractive surgery. It also looked at the pivotal role that artificial...
Viatris’ Phase III Blepharitis Ointment Candidate Fails to Reach Primary Endpoint
Viatris announced July 18 that a Phase III trial of pimecrolimus 0.3% (MR-139) ophthalmic ointment in blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks ...
Bioeq Licenses Lucentis Biosimilar to Bio Usawa for Sub-Saharan Africa
Swiss company Bioeq announced July 1 that it had licensed its Lucentis (ranibizumab) biosimilar to African biotech company Bio Usawa for marketing in sub-Saharan Africa under the brand name BioUcen...
Regulators in Canada Approve Xipere for Uveitic Macular Edema
Clearside Biomedical announced July 23 that Health Canada had approved Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use in uveitic macular edema. Bausch + Lomb has lice...
Novartis Reports Q2-2025 Lucentis Revenue of $173 Million
Novartis reported July 17 that its Q2-2025 Lucentis revenue outside the US was $173 million, a 37 percent decline (-39 percent cc) from $275 million in Q2-2024. The Swiss company said sales decline...
Onconetix to Merge with Glaucoma Drop Maker Ocuvex
Onconetix, of Cincinnati, Ohio, announced July 16 a definitive merger agreement with Ocuvex, maker of Omlonti (omidenepag isopropyl 0.002%) drops for glaucoma. The combined company will carry the O...
Beacon Licenses Abeona’s AAV204 Capsid for Select Ophthalmic Indications
Beacon Therapeutics has exercised its option to license Abeona Therapeutics’ AAV204 capsid for potential gene therapies for select ophthalmic indications, the companies announced July 1. Under the ...
US FDA Grants Fast Track Status to Sanofi’s GA Gene Therapy Candidate
France’s Sanofi announced July 16 that the US FDA had granted fast track designation to SAR446597, its gene therapy candidate for geographic atrophy (GA). SAR446597, designed for one-time intravitr...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.